Serge Lamisse
About Serge Lamisse
Serge Lamisse serves as the Executive Vice President at IBA, where he has contributed to the company's global expansion since 2014. With a background in finance and business administration, he has played a significant role in the development of advanced proton therapy solutions.
Current Role at IBA
Serge Lamisse has served as the Executive Vice President at IBA since 2014. In this role, he has played a significant part in the company's global expansion, overseeing the installation of systems across Europe, the United States, and emerging markets. His leadership has contributed to IBA's position in the industry, particularly in the field of proton therapy.
Previous Experience at IBA
Before becoming Executive Vice President, Serge Lamisse held the position of President Sales Particle Therapy at IBA from 2010 to 2015. During this five-year period, he focused on sales strategies and market development for particle therapy solutions, enhancing the company's outreach and influence in this specialized area of healthcare technology.
Board Membership at Neurotech SA
Serge Lamisse served as a Member of the Board at Neurotech SA from 2002 to 2013. His involvement with the organization spanned eleven years, during which he contributed to strategic decisions and governance, supporting the development of innovative technologies in the healthcare sector.
Educational Background
Serge Lamisse holds a Master of Business Administration from the Darla Moore School of Business, which he achieved in 1986. He also studied at Université Catholique De Louvain, where he earned a Master of Business Administration in Finance from 1987 to 1988, and a degree in Business Administration from 1981 to 1986. This educational foundation has equipped him with the skills necessary for his roles in business and management.
Involvement in Proton Therapy Development
Serge Lamisse has been actively involved in the development of proton therapy solutions. This technology is recognized as one of the most advanced forms of radiation therapy, providing targeted treatment options for cancer patients. His contributions in this area reflect his commitment to advancing healthcare technologies.